Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charlie Griffin

Family Medicine Vega Alta, PR Medical Doctor

NPI 1760946248 CMS profile 6832655

Urb. Haciendas Del Mar, 27 Calle 2, Vega Alta, PR 00692

Open in the dashboard

General payments

$2,512

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charlie Griffin of Vega Alta, PR is reported in the CMS Open Payments database as having received $2,512 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $714 16
2024 General $631 16
2023 General $378 11
2022 General $440 14
2021 General $275 15
2020 General $51 3
2019 General $22 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charlie Griffin
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Charlie Griffin were reported at $714. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Charlie Griffin Family Medicine median Middle half National median
2019 $22 $150 $41–$543 $163
2020 $51 $120 $32–$415 $114
2021 $275 $137 $35–$551 $132
2022 $440 $137 $37–$512 $149
2023 $378 $149 $42–$545 $160
2024 $631 $156 $44–$560 $164
2025 $714 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $446 16 payments
  2. E.R. Squibb & Sons, L.L.C. $391 7 payments
  3. AbbVie, Inc. $306 13 payments
  4. Medtronic, Inc. $282 4 payments
  5. PBG Puerto Rico LLC $194 9 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $166 5 payments
  7. Amgen Inc. $143 2 payments
  8. Merck Sharp & Dohme Corporation $103 3 payments
  9. Genzyme Corporation $89 1 payment
  10. AstraZeneca Pharmaceuticals LP $73 4 payments
  11. Other $319 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,512 77 payments
Products named General payments · program years 2019–2025
  1. XARELTO $446 16 payments
  2. ELIQUIS Cardiovascular $250 5 payments
  3. LifeVest $166 5 payments
  4. SKYRIZI $157 7 payments
  5. Reveal LINQ $151 1 payment
  6. ELIQUIS Cardiovascular;Metabolic Disease $135 6 payments
  7. Repatha $122 1 payment
  8. SOLITAIRE X $93 1 payment
  9. DUPIXENT $89 1 payment
  10. CAPVAXIVE $83 2 payments
  11. Other $847 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record